ZNTL Stock Analysis: Buy, Sell, or Hold?
ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock
$4.77
0.15 (3.25%)
▲
5d:
-0.21%
30d:
+35.51%
90d:
-14.21%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When ZNTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ZNTL shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ZNTL shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ZNTL is currently trading at $4.77, which is considered slightly high relative to its 30-day fair value range of $3.58 to $4.58.
Technical Outlook: Technically, ZNTL is in a uptrend. The price is approaching resistance at $4.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: ZNTL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.50 (+36.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZNTL is in a uptrend. The price is approaching resistance at $4.12. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: ZNTL has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.50 (+36.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.58 -
$4.58
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 36.3% below Wall St target ($6.50)
Trading Range Analysis
30-Day Trading Range
$3.58 -
$4.58
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.12
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.07
Wall Street Target
$6.50
(+36.3%)
Share & Embed Analysis
Last updated: July 14, 2026 5:20 PM ET
Data refreshes hourly during market hours. Next update: 6:20 PM
Data refreshes hourly during market hours. Next update: 6:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZNTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Vincent Vultaggio
SELL
6894 shares
2026-02-10
Ingmar Bruns
SELL
335 shares
2026-02-09
Vincent Vultaggio
SELL
3379 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 58 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 46 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 60 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 65 BUY |
